donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
06833 Sinco Pharmaceuticals
1.220
-0.010-0.81%
YOY
Do not show
Hide blank lines
(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31(Q6)2020/06/30
Per Share IndicaTor
Operating Cash Flow Per Share
107.06% 0.1996 201.05% 0.058 25.8% 0.0964 -171.77% -0.0574
Cash Flow Per Share
317.65% 0.1214 198.9% 0.0887 -158.56% -0.0558 -173.13% -0.0897
Operating Income Per Share
-8.18% 1.3218 46.14% 0.6017 85.45% 1.4395 14.44% 0.4117
Net Asset Per Share
110.85% 0.2448 230.37% 0.1703 278.06% 0.1161 97.84% 0.0515
Basic Earning Per Share
14.7% 0.0954 154.22% 0.0529 432.16% 0.0832 103.31% 0.0208
Diluted  Earning Per Share
14.7% 0.0954 154.22% 0.0529 432.16% 0.0832 103.31% 0.0208
Profitability
Gross Profit Ratio
34.97% 18.031% 8.99% 18.597% -27.26% 13.359% 0.48% 17.064%
Operating Profit Ratio
37.51% 9.711% 154.96% 12.574% 33.29% 7.062% -17.49% 4.932%
Net Profit Ratio
15.8% 6.674% 74.26% 8.887% 196.12% 5.763% 79.59% 5.100%
Earning Before Tax Ratio
24.69% 8.270% 128.32% 10.824% 84.46% 6.633% 16.49% 4.741%
ROE
-55.36% 50.451% -26.86% 37.345% 74.62% 113.012% 5.01% 51.059%
ROA
-8.02% 11.031% 45.96% 6.398% 264.3% 11.994% 43.61% 4.384%
Yield Quality
Operating Profit To Total Profits
10.29% 117.423% 11.67% 116.170% -27.74% 106.471% -29.17% 104.028%
Tax To Total Profits
-47.26% -19.299% -336.09% -17.891% 71.43% -13.106% 125.08% 7.578%
Operating Cash To Total Revenue
125.49% 15.104% 169.15% 9.642% -32.16% 6.698% -162.71% -13.944%
Capital Structure
Debt Assets Ratio
-19.89% 69.590% -11.56% 78.507% -7.61% 86.867% -1.42% 88.774%
Equity Multipler
-56.58% 3.2884 -47.17% 4.6528 -53.87% 7.5727 -10.34% 8.8063
Debt Equity Ratio
-65.4% 228.838% -53.81% 365.278% -57.98% 661.455% -12.69% 790.780%
Current Assets To tatal Assets
-2.15% 78.602% 9.32% 78.038% 10.69% 80.326% 72.71% 71.387%
Non Current Assets To Total Assets
8.76% 21.398% -23.24% 21.962% -28.28% 19.674% -51.23% 28.613%
Current Liabilities To tatal Liabilities
-7.15% 84.585% -13.22% 80.377% 25.3% 91.097% -7.28% 92.617%
Non Current Liabilities To Total Liabilities
73.15% 15.415% 165.77% 19.623% -67.38% 8.903% 6345.17% 7.383%
Solvency
Current Ratio
31.55% 1.3353 42.43% 1.2367 -4.38% 1.0151 88.96% 0.8683
Quick Ratio
62.4% 1.2509 171.5% 1.0945 32.55% 0.7703 -3.68% 0.4031
Operating Profit To Current Liabilities
85.4% 0.2709 178.12% 0.1513 22.45% 0.1461 -41.76% 0.0544
Operrating Cash Flow To Current Liabilities
204.02% 0.4213 175.43% 0.116 -37.68% 0.1386 -144.26% -0.1538
Share Equity Without Minority Interest To Total Liabilities
187.46% 0.437 114.02% 0.2738 134.66% 0.152 13.14% 0.1279
Operating Cash Flow To Total Liabilities
182.29% 0.3564 165.46% 0.0933 -21.92% 0.1262 -141.04% -0.1425
Operating Profit To Total Liabilities
72.15% 0.2291 141.37% 0.1216 53.42% 0.1331 -46% 0.0504
Operating Capacity
Current Assets Turnover(T)
-22.53% 2.0802 -23.88% 0.9085 8.44% 2.6852 -39.15% 1.1936
Fixed Assets Turnover(T)
-5.41% 10.3601 41.05% 4.5528 78.91% 10.9523 6.8% 3.2279
Total Assets Turnover(T)
-20.57% 1.6529 -16.24% 0.7199 23.03% 2.081 -20.03% 0.8595
Growth Ability
Operating Revenue GR 3Y
-16.24% 127.620% 7.93% 49.551% 314.32% 152.360% 631.89% 45.908%
Gross Income GR 3Y
-10.49% 134.267% 34.2% 50.731% 364.87% 149.997% 485.29% 37.802%
Operating Profit GR 3Y
-0.21% 188.803% 113.99% 451.553% 139.23% 189.203% 813.3% 211.018%
EBT GR 3Y
-1.98% 165.946% 55.8% 280.831% 159.56% 169.293% 478.54% 180.250%
Net Profit GR 3Y
-7.07% 151.588% 29.67% 256.509% 560.79% 163.117% 483.13% 197.823%
Net Profit Attributable To The Parent Company GR 3Y
-7.07% 151.589% 29.67% 256.513% 802.98% 163.117% 477.29% 197.826%
Total Assets GR 3Y
125.75% 115.448% 315.39% 61.733% 1811.81% 51.141% 49.38% -28.661%
Share Equity Without Minority Interest GR 3Y
4066.19% 1596.285% 94.04% -4.901% 55.2% -40.247% 10.6% -82.291%
Equity GR 3Y
4220.82% 1663.918% 94.47% -4.562% 55.14% -40.378% 10.59% -82.456%
Total Liabilities GR 3Y
-42.45% 55.714% 503.68% 99.713% -17.57% 96.814% 234.33% 16.518%
Basic Earning Per Share GR 3Y
-6.29% 150.356% 33.36% 253.733% 2028.24% 160.455% 426.02% 190.266%
Net Assets Per Share GR 3Y
3434.53% 1432.352% 94.1% -4.901% 52.43% -42.955% 10.08% -83.093%
Other Indicators
Currency Unit
HKDHKDHKDHKD

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Xingke Rong Pharmaceutical Holdings Co., Ltd. mainly provides marketing, promotion and channel management (MPCM) services in the pharmaceutical industry of the people's Republic of China. The company provides comprehensive MPCM services to small and medium-sized overseas pharmaceutical manufacturers that do not have independent marketing and promotion capabilities in China. Its main product is human serum albumin injection. The product is a human serum albumin produced by Octapharma for the treatment of hypovolemic and hypovolemic shock, abnormally high intracranial pressure, edema and ascites, as well as the prevention and treatment of hypoalbuminemia and neonatal hyperbilirubinemia. In addition, its products include Ankexin, McDonnell, Elsaif, Tate and Torot and so on.
CEO: Xiangbin Huang
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...